Enhances accessibility to cardiac care
Medkart announced the launch of Nicorandil tablets which remain stable at room temperature. The innovation eliminates the need for cold-chain storage, reducing logistical challenges and making the medication more accessible and affordable for patients across diverse regions.
Nicorandil is widely prescribed for the treatment of chronic stable angina. Due to its sensitivity to temperature and humidity, its storage has traditionally required stringent cold-chain logistics. This requirement often poses significant challenges, especially in rural and semi-urban areas where maintaining cold-chain infrastructure is difficult.
Medkart’s room-temperature stable Nicorandil tablets are manufactured under WHO-GMP-certified facilities, ensuring high-quality standards. By eliminating the need for refrigeration, the company significantly reduces distribution costs, allowing the medication to be priced up to 80 per cent lower than its branded counterparts.
“Our room-stable Nicorandil is more than a product—it’s an answer to India’s cold chain problem in heart care,” said Ankur Agarwal, Co-founder of Medkart. “We’re proving that innovation doesn’t have to be expensive—it has to be relevant.”
Dr Ramesh Mehta, a senior cardiologist based in Ahmedabad, added, “Ensuring that a cardiac drug like Nicorandil remains effective without refrigeration is a major step forward, particularly for patients in remote regions. We’ve long seen efficacy compromised due to storage issues. This advancement will save lives and improve treatment consistency.”
